[Frontiers in Bioscience 1, e15-25 March 1, 1996]
Reprints
PubMed
CAVEAT LECTOR



PHARMACOLOGICAL MANIPULATION OF THE COMPLEMENT SYSTEM IN HUMAN DISEASES.

Syed Shafi Asghar, Ph.D.

Division of Biochemistry and Immunology, Department of Dermatology, Academisch Medisch Centrum, University of Amsterdam, Amsterdam, The Netherlands

Received 12/08/95; Accepted 26/01/96; On-line 03/01/96

6. REFERENCES

1. S.S. Asghar: Pharmacological manipulation of the complement system. Pharm Rev 36, 223-44 (1984)

2. S.S. Asghar: Pharmacological manipulation of complement in dermatology. In: Skin Immune System (ed. J.D. Bos). 2nd edition. CRC Press, Inc. Boca Raton, Florida. 1996; in press.

3. M.K. Liszewiski & J.P. Atkinson. The complement system. In: Fundamental Immunology (ed. W.A. Paul). Raven press. New York. 1993; 917-39

4. S.S. Asghar: Complement in physiopathology of skin. In: Skin Immune system (ed. J.D.Bos). CRC Press, Inc. Boca Raton, Florida. 1990; 207-41

5. H.J. Muller-Eberhard: Molecular organization and function of the complement system. Ann Rev Biochem 57, 321-47 (1988)

6. S.S. Asghar: Complement and complement regulatory proteins. In: Skin Immune system (ed. J.D.Bos). CRC Press, Inc. Boca Raton, Florida. 1996; in press.

7. S.S. Asghar: Membrane regulators of complement activation and their aberrant expression in disease. Lab Invest 72, 254-71 (1995)

8. B.P. Morgan & S. Meri: Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 15, 369-96 (1994)

9. D. Hourcade, V.M. Holers, J.P. Atkinson: The regulators of complement activation (RCA) gene cluster. Adv Immunol 45, 381-416 (1989)

10. Z.N. Oltvai, E.C.C. Wong, J.P. Atkinson, K.S.K. Tung: C1-inhibitor deficiency: Molecular and Immunological basis of hereditary and acquired angioedema. Lab Invest 65, 381-8 (1991)

11. A.E. Davis III: C1 Inhibitor and hereditary angioneurotic edema. Ann Rev Immunol 6, 595-628 (1988)

12. M. Hessing: The interaction between complement C4b-binding protein and the vitamin K dependent protein S forms a link between blood coagulation and complement system. Biochem J 227, 581-92 (1991)

13. R.D. Campbell, S.K.A. Law, K.B.M. Reid, R.B. Sim: Structure, organization and regulation of the complement genes. Ann Rev Immunol 6, 161-95 (1988)

14. R.B. Sim, K. Colbe, M.A. Mc Aleer, O. Doninguez & V.M. Dee: Genetics and deficiencies of soluble regulatory proteins of the complement system. Int Rev Immunol 10, 65-86 (1993)

15. P.F. Zipfel & C. Skerka: Complement factor H and related proteins: an expanding family of complement-regulatory proteins? Immunology Today 15, 121-6 (1994)

16. D.E. Jenne & J. Tschopp: Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci 17, 154-9 (1992)

17. K.T. Preissner: Structure and biological role of vitronectin. Ann Rev Cell Biol 7, 275-310 (1991)

18. D.M. Lubin & J.P. Atkinson: Decay-accelerating factor: Biochemistry, molecular biology, and function. Ann Rev Immunol 7, 35-58 (1989)

19. A. Nicolson-Weller: Decay accelerating factor (CD55). Curr Top Microbiol Immunol 178, 7-30 (1992)

20. M.K. Liszewski, T.W. Post & J.P. Atkinson: Membrane cofactor protein (MCP or CD46): Newest member of the regulators of complement activation gene cluster. Ann Rev Immunol 9, 431-55 (1991)

21. J.M. Ahearn & D.T. Fearon: Structure and function of the complement receptor CR1 (CD35) and CR2 (CD21). Adv Immunol 46, 183-219 (1989)

22. W.W. Wong: Structural and functional correlation of the human complement receptor type 1. J Invest Dermatol 94 (suppl), 64-67 S (1990)

23. G.T. Venneker & S.S. Asghar: CD59: A molecule involved in antigen presentation as well as down regulation of membrane attack complex. Exp Clin Immunogen 9, 33-47 (1992)

24. L.A. Walsh, M. Tone, S. Thiru, H. Waldmann: CD59 antigen - a multifunctional molecule. Tissue antigens 40, 213-220 (1992)

25. A. Davies & P.J. Lachman: Membrane defense against complement lysis: The structure and biological properties of CD59. Immunol Res 12, 258-75 (1993)

26. L.S. Zalman: Homologous restriction factor. Curr Topics Microbiol Immunol 178, 87-99 (1992)

27. A.J. Tenner & M.M Frank: Activator bound C1 is less susceptible to inactivation by C1 inhibitor than is fluid phase C1. J Immunol 137: 625-30 (1986)

28. A. Leimgruber, W.A. Jaques & P.J. Spaeth: Hereditary angioedema- Uncomplicated Maxillofacial surgery using short term C1-inhibitor replacement therapy. Int Arch Allergy Immunol 101, 107-12 (1993)

29. J. Gadek, S.W. Hosea, J.A. Gelfand & M.M. Frank: Response of variant hereditary angioneurotic edema phenotypes to danazol therapy. Genetic implications. J Clin Invest 64, 280-6 (1979)

30. R. Guerrero, F. Velasco, M. Rodriguez, A. Lopez, R. Rojas, M.A. Alvarez, R. Villalba, V. Rubio, A. Torres & D. del Castillo: Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor. J. Clin Invest 91, 2754-60 (1993)

31. C.E. Hack, A.C. Ogilia, B. Eisele, P.M. Jansen, J. Wagstaff & L.G Thijs: Initial studies on administration of C1-esterase inhibitor to patients with septic shock or with a vascular leakage syndrome induced by interleukin-2 therapy. Progr Clin Biol Research 388, 335-57 (1994)

32. R.I. Schiff: Intravenous gammaglobulin: pharmacology, clinical uses and mechanism of action. Pediatr Allergy Immunol 5, 63-7 (1994)

33. J.M. Dwyer: Manipulating the immune system with immune globulins. New Engl J Med 326, 107-16 (1992)

34. V.R. De Souza, S.V. Kaveri & M.D. Kazatchkine: Intravenous Immunoglobulin (IVIG) in the treatment of autoimmune and inflammatory diseases. Clin Exp Rheumatol 11 (Suppl), S 33-6 (1993)

35. K.E. Roux & D.L. Tankersley: A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol 144, 1387-95 (1990)

36. M.G. Macey & A.C. Newland: CD4 and CD8 subpopulation changes during high dose intravenous immunoglobulin treatment. Br J Hematol 76, 513-20 (1990)

37. I.N. van Schaik, I. Lundkvist, M. Vermeulen & A. Brand: Ployvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol 12, 1-10 (1992)

38. D.Engelhard, J.L. Waner, N.Kapoor & R.A.Good: Effect of intravenous immunoglobulin on natural killer cell activity: possible association with autoimmune neutropenia and idiopathic thrombocytopenia. J Pediatr 108, 77-81 (1986)

39. T. Shimozato, M. Iwata, H. Kawada & N. Tamura: Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3':5'-monophosphate levels, resulting in suppression of tumor necrosis factor alpha and interleukin-1 production. Immunology 72, 497-501 (1991)

40. J.A. Schifferli, L. Didierjean & J.H. Saurat: Immunomodulatory effects of intravenous immunoglobulin G. J Rheumatol 18, 937-9 (1991)

41. W.P. Arend, M.F. Smith, R.W.Janson & F.G. Joslin: IL-1 receptor antagonist and IL-1 beta production in human monocytes are regulated differently. J Immunol 147,1530-6 (1991)

42. M. Qi & J.A.Schifferli: Inhibition of complement activation by intravenous immunoglobulins. Arthritis Rheum 38, 146 (1995)

43. M. Basta, L.F. Fries & M.M. Frank: High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 77, 376-80 (1991)

44. P. Berchtold P & R. Mc Millen: Intravenous immunoglobulin: new aspects of mechanism of action in chronic ITP. In: Immunotherapy with Intravenous Immunoglobulins (ed. P. Imbach), Academic Press, London. 1991; 245-52

45. J.M. Lusher & I. Warrier: Use of intravenous immunoglobulin in children and adolescents with idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Am J Med 4 (Suppl A), 10-6 (1987)

46. J.P. Bussel. The use of intravenous-g-globulin in idiopathic thrombocytopenic purpura. Clin Immunol Immunopathol 53, S 147-55 (1989)

47. S.T. Shulman: Kawasaki disease and IVIG: what is going on here ? In: Immunotherapy with Intravenous Immunoglobulins (ed. P. Imbach). Academic Press, London. 1991; 261-8

48. J.W. Newburger, M. Takahashi, J.C. Burns, A.S. Beiser, K.J. Chung, C.E. Duffy, M.P. Golde, W.H. Mason, V. Reddy, S.P. Sanders, S.T. Shulman, J.W. Wiggins, R.W. Hicks, D.R. Fulton, A.B. Lewis, D.Y.M. Leung, T. Colton, F.S. Rosen & M.E. Malish: The treatment of Kawasaki syndrome with intravenous gamma globulins. New Engl J Med 315, 341-7 (1986)

49. S. Nonoyama: Immunological abnormalities and endothelial cell injury in Kawasaki disease. Acta Pediatr Jpn 33, 752-5 (1991)

50. E.S. Lekora, L. Joffe & M.P. Golde: Antigenic recognition of intravenous gamma globulin of selected bacteria isolated from throats of patients with Kawasaki syndrome. Pediatr Infect Dis J 9, 620-3 (1990)

51. E. Arsura: Experience with intravenous immunoglobulin in myasthenia gravis. Clin Immunol Immunopathol 53, S 170-9 (1989)

52. P. Gajdos: Intravenous immunoglobulin in myasthenia gravis. Clin Exp Immunol 97 (Suppl 1), 49-51 (1994)

53. P.A. van Doorn, M. Vermeulen, A. Brand, P.G.H. Mulder & H.F.M. Busch: Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol 48,217-220 (1991)

54. C. Coulam, A. Peters, J. Mc Intyre & W. Faulk: The use of IVIG for the treatment of recurrent spontaneous abortion. In: Immunotherapy with intravenous immunoglobulins (ed. P. Imbach). Academic Press, London, 1991, 395-400

55. O. Heine and G. Mueller-Eckhardt: Intravenous immune globulin in recurrent abortion. Clin Exp Immunol 97 (Suppl 1), 39-42 (1994)

56. A.K. Gupta, N.H. Shear & D.N. Sauder: Efficacy of human intravenous immune globulin in pyoderma gangrenosum. J Am Acad Dermatol 32, 140-2 (1995)

57. C. Mohr, C. Sunderkotter, A. Hilderbrand, K. Biel, A. Rutter, G.H. Rutter, T.A. Leuger & G. Kolde: Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins. Br J Dermatol 132, 824-6 (1885)

58. A.K. Sharma & M.K. Pangburn: Biologically active recombinant factor H: synthesis and secretion by baculovirus system. Gene 143, 301-2 (1994)

59. R.G. Trapp, M. Fletcher, J. Forristall & C.D. West: C4 binding protein deficiency in a patient with atypical Behcet's disease. J Rheumatol 14, 135-8 (1987)

60. A.J. Bonnin, H.J. Zeitz & A. Gewurz: Complement factor I deficiency with recurrent aseptic meningitis. Arch Intern Med 153, 1380-3 (1993)

61. J.B. Ziegler, C.A. Alper, R.S. Rosen, P.J. Lachmann & L. Sherington: Restoration by purified C3b inactivator of complement mediated function in vivo in a patient with C3b inactivator deficiency. J Clin Invest 55: 668-72 (1975)

62. M.E. Medof, E.I. Walter, J.L. Rutgers, D.M. Knowles & V. Nussenzeweig V: Identification of the complement decay accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 165, 848-64 (1987)

63. T. Hara, S. Kuriyama, H. Kiyohara, M. Nagase, M. Matsumoto & T. Saya: Soluble forms of membrane cofactor protein (CD 46, MCP) are present in plasma, tears and seminal fluid in normal subjects. Clin Exp Immunol 89: 490-4 (1992)

64. S. Yoon & D.T. Fearon: Characterization of a soluble form of the C3b/C4b receptor (CR1) in human plasma. J Immunol 134, 3332-8 (1985)

65. P. Moran, H. Beasley, A. Gorrell, E. Martin, P. Gribling, H. Fuchs, N. Gillet, L.E. Burton & I.W. Caras: Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. J Immunol 149, 1736-43 (1992)

66. D.M. Lubin & K.E Coyne: Phospholipid anchored and transmembrane versions of either decay- accelerating factor or membrane cofactor protein show equal efficiency in protection from complement mediated cell damage. J Exp Med 174, 35-44 (1991)

67. G.C. Yeh, H.C. Marsh Jr, G.R. Carson, L. Berman, M.F. Concino, S.M. Scesney, R.E. Kuestner, R. Skibbens, K.A. Donahue & S.H. Ip: Recombinant soluble human complement receptor type 1 inhibits inflammation in the reverse passive Arthus reaction in rats. J Immunol 146, 250-6 (1991)

68. K.R. Kalli, P. Hsu & D.T. Fearon: Therapeutic uses of recombinant complement proteins. Springer Semin Immunopathol 15, 417-31 (1994)

69. J.L. Platt: A perspective on xenograft rejection and accommodation. Immunol Rev 141, 127-49 (1994). 70. W.M. Baldwin 3rd, S.K. Pruit, R.B. Brauer, M.R. Daha & F. Sanfilippo: Complement in organ transplantation. Transplantation 59, 797-808 (1995)

71. A.P. Dalmasso: The complement system in xenotransplantation. Immunopharmacology 24, 149-60 (1992)

72. D.H. Sachs: The pig as a potential xenograft donor. Veterin Immunol Immunopathol 43, 185-91 (1994)

73. E. Cozzi, G.A. Langford, L. Wright, A. Tucker, M. Yannoutsos, A. Richards, A. Rosengards, K. Elsome, R. Lancaster & D.J.G. White: Comparative analysis of human DAF expression in the tissues of transgenic pigs and man. Transpl Proceed 27, 319-20 (1995)

74. G. Rosengard, N. Cary, J. Horseley, C. Belcher, G. Lagford, E. Cozzi, J. Wallwork, D.J.G. White: Endothelial expression of human decay accelerating factor in transgenic pig tissue. A potential approach for human complement inactivation in discordant xenografts. Transpl Proc 27, 326-27 (1995)

75. F.D. Moore Jr: Therapeutic regulation of the complement system in acute injury states. Adv Immunol 56, 267-99 (1994)

76. H.J. Weisman, T. Bartow, M.K. Leppo, H.C. Marsh Jr, G,R. Carson, M.F. Concino, M.P. Boyle, K.H. Roux, M.L. Wiesfeldt & D.T. Fearon: Soluble human complement receptor type 1 : in vivo inhibitor of complement suppresses post-ischemic myocardial inflammation and necrosis. Science 249, 146-51 (1990)

77. J. Hill, T.H. Lindsay, F. Ortiz, C.G. Yeh, H.B. Hechtman, F.D. Moore Jr: Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J Immunol 149, 1723-8 (1992)

78. M. Pemberton, G. Anderson, V. Vetvicka, D.E. Justus & G.D. Ross. Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia and reperfusion injury of skeletal muscle. J Immunol 150, 5104-13 (1993)

79. T. Morisaki, T. Goya, H. Toh, K. Nishihara & Toisu M: The anti-Mac-1 monoclonal antibody inhibits neutrophil sequestration in lung and liver in a septic murine model. Clin Immunol Immunopathol 61, 365-75 (1991)

80. P. Grob, M. Holch, W. Fierz, W. Glinz & S. Geroulanos: Immunodeficiency after major trauma and selective surgery. Pediatr Infect Dis J 7, S37-42 (1988)

81. M.S. Mulligan, C.G. Yeh, A.R. Rudolph & P.A. Ward: Protective effects of soluble CR1 in complement and neutrophil-mediated injury. J Immunol 148, 1479-85 (1992)

82. S.K. Pruitt, A.D. Kirk, R.R. Bollinger, H.C. Marsh, B.H. Collins, J.L. Levin, J.R. Mault, J.S. Heinle, S. Ibrahim, A.R. Rudolph, W.M. Baldwin & F. Sanfilippo: The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 57, 363-70 (1994)

83. S.K. Pruitt & R.R. Bollinger: The effect of soluble complement receptor type 1 on hyperacute allograft rejection. J Surg Res 50, 350-5 (1991)

84. W. Xia, D.T. Fearon, F.D. Moore Jr, F.J. Schoen, F. Ortiz & RL Kirkman: Prolongation of guinea pig cardiac xenograft survival in rats by soluble human complement receptor type 1. Trans Proc 24: 479-80 (1992)

85. B.P. Morgan: Complement regulatory molecules: application to therapy and transplantation. Immunology Today 16, 257-9 (1995)

86. U.S. Ryan: Blockade of complement using soluble complement receptors. Cambridge Healthcare Institute's Conference on Prevention of Reperfusion Injury. Omni Royal Orleans, New Orleans, Louisiana, USA. February 20-21, (1995)

87. W.L. Fodor, B.L. Williams, L.A. Matis, J.A. Madri, S.A. Rollins, J.W. Knight, W. Velander & S.P. Squinto: Expression of functional complement inhibitor in a transgenic pig as a model for prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sciences USA. 91, 11153-7 (1994)

[Table of Contents] [Previous Section]